Comparative Pharmacology
Head-to-head clinical analysis: ESKALITH versus LITHONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESKALITH versus LITHONATE.
ESKALITH vs LITHONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lithium modulates neurotransmission by inhibiting inositol monophosphatase, leading to reduced phosphoinositide signaling; also inhibits glycogen synthase kinase-3 (GSK-3) and alters neuronal excitability via effects on sodium transport and neurotransmitter release.
Lithium modulates neurotransmitter activity in the central nervous system, including inhibition of inositol monophosphatase, leading to reduced phosphoinositide signaling; alters G-protein coupled receptor signaling; and inhibits glycogen synthase kinase-3 (GSK-3). It also affects ion transport, including sodium and potassium, and stabilizes neuronal excitability.
Lithium carbonate extended-release: 300-600 mg orally twice daily, titrated to serum levels 0.6-1.2 mEq/L. Immediate-release: 300-600 mg three times daily.
300-600 mg orally 2-3 times daily for acute mania; 600-1200 mg/day in divided doses for maintenance. Titrate to serum lithium level 0.8-1.2 mEq/L (acute) or 0.6-1.2 mEq/L (maintenance).
None Documented
None Documented
Terminal elimination half-life: 18-24 hours (range 12-27 hours) in adults; may be prolonged in elderly or renal impairment. Steady-state achieved in 5-7 days.
Terminal elimination half-life 18-36 hours in young adults, up to 48-72 hours in elderly or with renal impairment; steady state reached in 5-7 days.
Renal: >95% excreted unchanged in urine. Biliary/fecal: negligible (<1%).
Primarily renal excretion (>95% as unchanged lithium); less than 5% excreted in feces via bile.
Category C
Category C
Mood Stabilizer
Mood Stabilizer